km-2210 and Leukopenia

km-2210 has been researched along with Leukopenia* in 2 studies

Other Studies

2 other study(ies) available for km-2210 and Leukopenia

Article	Year
[Early phase II trial of bestrabucil in hematological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6 Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%). Topics: Adult; Aged; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukopenia; Lymphoma; Male; Middle Aged; Thrombocytopenia	1986
[Phase I study of bestrabucil (KM 2210)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6 A phase I study was performed on a newly developed antitumor agent, Bestrabucil (KM 2210). The study was started at an initial dose of 1 n 25 mg/body, and gradually increased up to 32n 800 mg/body. With single (35 patients) and five-consecutive-day (36 patients) administration, the dose-limiting factor was found to be tarry stool, remarkable decrease in hemoglobin content, and strong nipple and breast pain. The maximum tolerated dose (MTD) was concluded to be around 700 to 800 mg/body. With long-term administration (the longest term, 20 weeks, 36 patients), the dose-limiting factor was concluded to be a decrease in the peripheral leukocyte count when the total amount administered reached about 10 g. Side effects on the alimentary system due to this agent, such as vomiting, nausea and anorexia, were observed. In addition, mastalgia and genital bleeding due to released estrogen were also seen, especially in the case of long-term administration. Topics: Adult; Aged; Animals; Anorexia; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Neoplasms; Pain; Rats	1986

Article

Year

[Early phase II trial of bestrabucil in hematological malignancies].

Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6

Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%).

Topics: Adult; Aged; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukopenia; Lymphoma; Male; Middle Aged; Thrombocytopenia

1986

[Phase I study of bestrabucil (KM 2210)].

Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6

A phase I study was performed on a newly developed antitumor agent, Bestrabucil (KM 2210). The study was started at an initial dose of 1 n 25 mg/body, and gradually increased up to 32n 800 mg/body. With single (35 patients) and five-consecutive-day (36 patients) administration, the dose-limiting factor was found to be tarry stool, remarkable decrease in hemoglobin content, and strong nipple and breast pain. The maximum tolerated dose (MTD) was concluded to be around 700 to 800 mg/body. With long-term administration (the longest term, 20 weeks, 36 patients), the dose-limiting factor was concluded to be a decrease in the peripheral leukocyte count when the total amount administered reached about 10 g. Side effects on the alimentary system due to this agent, such as vomiting, nausea and anorexia, were observed. In addition, mastalgia and genital bleeding due to released estrogen were also seen, especially in the case of long-term administration.

Topics: Adult; Aged; Animals; Anorexia; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Neoplasms; Pain; Rats

1986